Elevated levels of serum antibodies against alpha-1, 6-glucan in patients with systemic lupus erythematosus or rheumatoid arthritis

Abstract

This study was undertaken to investigate whether levels of anti-alpha-1, 6-glucan antibodies in human sera correlate with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Serum samples were collected from patients with SLE (n = 30), RA (n = 30) and healthy adult volunteers. IgG, IgA and IgM levels against alpha-1, 6-glucan were measured using enzyme linked immunosorbent assays. Anti-alpha-1, 6-glucan IgG prevalence was raised in patients with active SLE (73.3%) and RA (60%) compared with healthy controls (13.3%). Strong correlation between anti-alpha-1,6-glucan-IgG levels and anti-perinuclear factor (r = 0.642; p<0.05) in RA patients or anti-nuclear antibodies (r = 0.675; p<0.05) in SLE patients was observed. No significant differences in anti-alpha-1,6-glucan-IgA or-IgM levels were noted between different groups. We conclude that anti-alpha-1,6-glucan-IgG levels were significantly elevated in patients with SLE or RA and positively correlated with disease activity.

Keywords

autoantibody / anti-alpha-1 / 6-glucan / autoimmune diseases / systemic lupus erythematosus / rheumatoid arthritis

References

[1] Anastase, S., Letourneur, D., and Jozefonvicz, J. (1996). Affinity chromatography of human anti-dextran antibodies. Isolation of two distinct populations. J Chromatogr B Biomed Appl 686, 141–150 8971594.
[2] Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315–324 3358796.
[3] Asahi, T., Yamamoto, T., and Kutsuki, H. (2003). Blood purification therapies using dextran sulfate cellulose columns Liposorber and Selesorb. Ther Apher Dial 7, 73–77 12921119.
[4] Bourne, J.T., Kumar, P., Huskisson, E.C., Mageed, R., Unsworth, D.J., and Wojtulewski, J.A. (1985). Arthritis and coeliac disease. Ann Rheum Dis 44, 592–598 3876079.
[5] Braun, N., Jünger, M., Klein, R., Gutenberger, S., Guagnin, M., and Risler, T. (2002). Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. Ther Apher 6, 471–477 12460414.
[6] Chacko, B.K., and Appukuttan, P.S. (2003). Dextran-binding human plasma antibody recognizes bacterial and yeast antigens and is inhibited by glucose concentrations reached in diabetic sera. Mol Immunol 39, 933–939 12695119.
[7] Dai, H., Li, Z., Zhang, Y., Lv, P., and Gao, X.M. (2009a). Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus 18, 1087–1090 19762383.
[8] Dai, H., Li, Z., Zhang, Y., Lv, P., and Gao, X.M. (2009b). Elevated levels of serum IgA against Saccharomyces cerevisiae mannan in patients with rheumatoid arthritis. Cell Mol Immunol 6, 361–366 19887049.
[9] Dinglasan, R.R., Valenzuela, J.G., and Azad, A.F. (2005). Sugar epitopes as potential universal disease transmission blocking targets. Insect Biochem Mol Biol 35, 1–10 15607650.
[10] Galili, U. (2001). The alpha-gal epitope (Gal alpha 1-3Gal beta 1-4GlcNAc-R) in xenotransplantation. Biochimie 83, 557–563 11522383.
[11] Galili, U. (2005). The alpha-gal epitope and the anti-Gal antibody in xenotransplantation and in cancer immunotherapy. Immunol Cell Biol 83, 674–686 16266320.
[12] Greenstein, A.J., Janowitz, H.D., and Sachar, D.B. (1976). The extra-intestinal complications of Crohn’s disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55, 401–412 957999.
[13] Gupta, D., Kaltner, H., Dong, X., Gabius, H.J., and Brewer, C.F. (1996). Comparative cross-linking activities of lactose-specific plant and animal lectins and a natural lactose-binding immunoglobulin G fraction from human serum with asialofetuin. Glycobiology 6, 843–849 9023547.
[14] Hashimoto, H., Tsuda, H., Kanai, Y., Kobayashi, S., Hirose, S., Shinoura, H., Yokohari, R., Kinoshita, M., Aotsuka, S., Yamada, H., (1991). Selective removal of anti-DNA and anticardiolipin antibodies by adsorbent plasmapheresis using dextran sulfate columns in patients with systemic lupus erythematosus. J Rheumatol 18, 545–551 2066947.
[15] Huang, C.Y., Thayer, D.A., Chang, A.Y., Best, M.D., Hoffmann, J., Head, S., and Wong, C.H. (2006). Carbohydrate microarray for profiling the antibodies interacting with Globo H tumor antigen. Proc Natl Acad Sci U S A 103, 15–20 16373501.
[16] Kutsuki, H., Takata, S., Yamamoto, K., and Tani, N. (1998). Therapeutic selective adsorption of anti-DNA antibody using dextran sulfate cellulose column (Selesorb) for the treatment of systemic lupus erythematosus. Ther Apher 2, 18–24 10227784.
[17] Mageed, R.A., and Zack, D.J. (2002). Cross-reactivity and pathogenicity of anti-DNA autoantibodies in systemic lupus erythematosus. Lupus 11, 783–786 12529040.
[18] Matsuki, Y., Suzuki, K., Kawakami, M., Ishizuka, T., Kawaguchi, Y., Hidaka, T., and Nakamura, H. (1996). High-avidity anti-DNA antibody removal from the serum of systemic lupus erythematosus patients by adsorption using dextran sulfate cellulose columns. J Clin Apher 11, 30–35 8722720.
[19] Pal, S., Bandyopadhyay, S., Chatterjee, M., Bhattacharya, D.K., Minto, L., Hall, A.G., and Mandal, C. (2004). Antibodies against 9-O-acetylated sialoglycans: a potent marker to monitor clinical status in childhood acute lymphoblastic leukemia. Clin Biochem 37, 395–403 15087256.
[20] Suzuki, K. (2000). The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther Apher 4, 239–243 10910027.
[21] Tan, E.M., Cohen, A.S., Fries, J.F., Masi, A.T., McShane, D.J., Rothfield, N.F., Schaller, J.G., Talal, N., and Winchester, R.J. (1982). The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25, 1271–1277 7138600.
[22] Zhao, Z., Weinstein, E., Tuzova, M., Davidson, A., Mundel, P., Marambio, P., and Putterman, C. (2005). Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 52, 522–530 15693007.